AG真人官方

Vimeo, Inc. (VMEO) 鈥� SEC Form 4

Non-employee director Adam Cahan was credited with 946.97 common share units on 17 Jul 2025 under the company鈥檚 2021 Deferred Compensation Plan for Directors. The administrative credit was recorded at an implied price of $3.96 and classified as an acquisition (Code 鈥淎鈥�).

After the grant, Cahan鈥檚 direct beneficial ownership rises to 45,390.97 shares, which now comprises the newly issued units plus 44,444 previously awarded restricted stock units. No shares were sold and no derivative securities were exercised or disposed of.

The filing signals a small鈥攍argely routine鈥攊ncrement in insider exposure, reflecting standard director compensation rather than an open-market purchase.

On 16 July 2025, The Goldman Sachs Group, Inc. filed a Form 8-K to announce its second-quarter 2025 results under Item 2.02. The filing itself provides no financial metrics; detailed numbers are contained in Exhibit 99.1, a press release that is deemed 鈥渇iled鈥� for Exchange Act purposes.

Under Item 7.01, the firm will host a conference call at 9:30 a.m. ET on the same day. The accompanying slide deck (Exhibit 99.2) is furnished, meaning it is not subject to Section 18 liability. Additional exhibits include iXBRL cover-page data (101) and the related interactive file (104). The report is signed by CFO Denis P. Coleman III. No other material events, transactions or guidance were disclosed; investors should consult the attached press release and presentation for full financial details.

GS Finance Corp., fully guaranteed by The Goldman Sachs Group, Inc., is offering $3 million of Autocallable Contingent Coupon Underlier-Linked Notes due July 13, 2028. The notes reference three equity underliers: the S&P 500庐 Index (6,225.52 initial level), Nasdaq-100 Index庐 (22,702.25) and iShares庐 Russell 2000 ETF ($221.25). Investors receive a monthly coupon of $8.75 per $1,000 face amount (0.875%, up to 10.5% p.a.) only if, on the related observation date, each underlier closes at or above 70 % of its initial level. No coupon is paid if any underlier breaches that trigger.

The issuer may automatically call the notes at par plus the monthly coupon on any quarterly call observation date (Jan, Apr, Jul, Oct) beginning January 2026 if all underliers are at or above their initial levels. If not called, principal repayment at maturity depends on the least-performing underlier: investors receive par if every underlier is at least 70 % of its initial level; otherwise they incur a loss matching the percentage decline of the worst underlier, potentially down to zero. There is no upside participation beyond par.

The notes are senior unsecured obligations of GS Finance Corp. with a 0.2% underwriting discount; estimated value at pricing was stated to be not less than 100 % of face. Key risks highlighted include issuer/guarantor credit risk, potential loss of entire investment, contingent coupons that may never be paid, limited secondary liquidity, market disruption adjustments and complex U.S. tax treatment. The product is part of Goldman鈥檚 Medium-Term Notes, Series F program and was issued under prospectus supplement dated February 14, 2025.

Constellation Brands, Inc. (STZ) 鈥� Form 4 insider filing dated 07/14/2025

Non-Executive Chair and Director Christopher J. Baldwin reported the vesting and settlement of 503 Restricted Stock Units (RSUs) on 07/10/2025 (transaction code M). Each RSU converted into one share of Class A common stock at no cost, increasing his directly owned stake to 2,711 shares.

Indirect holdings remain unchanged at 32 shares (15 held by his spouse and 17 held in two family trusts). All previously outstanding RSUs involved in this filing were fully settled, leaving zero derivative securities outstanding for Baldwin.

• No open-market purchase or sale was disclosed; the activity reflects routine equity compensation vesting.
• The transaction does not affect company operations or financials, but modestly aligns board leadership incentives with shareholder value through additional share ownership.

Steelcase, Inc. (NYSE:SCS) has filed a Form 144 indicating that insider Robert Krestakos intends to sell 12,000 common shares through Morgan Stanley Smith Barney on or about 11 July 2025. The planned sale is valued at roughly $127,546, a negligible 0.011% of the 114.7 million shares outstanding. These shares were acquired via performance and restricted stock awards granted between 2018 and 2021. Over the last three months the same insider sold an additional 6,000 shares for proceeds of approximately $61,000. No operational, earnings, or strategic disclosures accompany this filing, making it chiefly an administrative notice of modest insider selling.

Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) disclosed that the U.S. FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) of UX111 (ABO-102), its AAV gene therapy for Sanfilippo syndrome type A. The agency is requesting additional chemistry, manufacturing and controls (CMC) information and remediation of observations from recent facility inspections. The CRL does not cite deficiencies in the clinical data package; the FDA characterized neurodevelopmental and biomarker data as robust and asked only for updated data in the resubmission.

The company believes the cited issues are facility- and process-related and 鈥渞eadily addressable.鈥� Management plans to engage the FDA over the coming months, then resubmit the BLA, which would trigger a new review period of up to six months. No timeline for resubmission was provided, but the disclosure implies at least a several-month delay to potential approval and launch.

Investor takeaway: Receipt of a CRL materially delays potential commercialization and revenue generation from UX111, introduces additional regulatory risk, and may elevate operating costs as manufacturing processes are refined. Mitigating factors include the absence of clinical concerns and the company鈥檚 confidence that CMC issues can be resolved.

Happy City Holdings Limited (HCHL) Form 6-K 鈥� Key Points

• Dominari Securities, representative of the IPO underwriters, partially exercised its over-allotment option on 7 July 2025, purchasing 112,000 Class A Ordinary Shares at the public offering price of US$5.00 per share.
• The closing of this transaction occurred on 11 July 2025.
• Including the over-allotment shares, total gross IPO proceeds now amount to US$6.06 million, before underwriting discounts and related expenses.
• A press release detailing the transaction is filed as Exhibit 99.1.

This filing is informational and does not constitute an offer or solicitation to sell securities.

GS Finance Corp., guaranteed by The Goldman Sachs Group, Inc., is marketing Contingent Income Auto-Callable Securities linked to the Class A common stock of Rivian Automotive, Inc. (RIVN). The notes are expected to price on or about July 17 2025, settle on July 22 2025 and, unless automatically called, mature on July 20 2028.

The securities pay a contingent quarterly coupon of at least $61.875 per $1,000 face value if, on the relevant observation date, Rivian鈥檚 share price is at or above the 60 % downside threshold. No coupon is paid if the threshold is breached. Beginning with the first observation date on October 17 2025, the notes will be automatically called if Rivian鈥檚 closing price is at or above the initial share price; in that event investors receive the $1,000 principal plus the due coupon, and no further payments.

At maturity, investors receive (i) the full principal plus the final coupon if Rivian closes at or above 60 % of the initial price, or (ii) principal multiplied by the share-performance factor if the stock finishes below the threshold, exposing holders to losses in line with the underlying鈥攑otentially down to zero. The estimated value at pricing is $900鈥�$960, below the $1,000 issue price. Other disclosed risks include issuer and guarantor credit exposure, Rivian鈥檚 limited trading history, the possibility of no coupon payments, limited liquidity and adverse tax treatment.